Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBoston Scientific Corporation
About this trial
Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Eligibility criteria
Qualifiers
Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).
Signed a valid, IRB/EC-approved informed consent form.
Disqualifiers
Meets any contraindications per locally applicable Instructions for Use (IFU).
Trial design
Treatments tested in this trial
- Intracept™ Intraosseous Nerve Ablation
Treatment groups
1,500 Participants
are divided into 1 treatment groupLocations
18Arizona
Flagstaff Bone & Joint86001, Flagstaff United States
Innovative Pain and Wellness85014, Phoenix United States
California
MarinHealth Spine Institute94939, Larkspur United States
Connecticut
The Spine Wellness Center in Westport06880, Westport United States
Sponsors and collaborators
Boston Scientific Corporation
Lead sponsor
Source ClinicalTrials.gov